Regeneus Ltd Stock Market Press Releases and Company Profile
Appendix 4C - Quarterly
Appendix 4C - Quarterly

Sydney, July 26, 2017 AEST (ABN Newswire) - Regeneus Ltd (googlechartASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.

The highlights for the quarterly reporting period include:

- On 30 June, Regeneus received a milestone payment of US$1 million from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. Regeneus reported on the positive results of the trial on 22 May 2017. Licence fees received from AGC during the financial year are in total US$6.5 million (A$8.9 million).

- Cash outflow for the quarter was $0.75 million. Cash outflow from operating activities, after allowing for the receipt of the Japanese licence fee net of associated cost, was $2.0 million, an increase of 10% over the prior quarter driven by the increase of R&D expenditure particularly in projects associated with Progenza and the development of other strategic assets including RGSH4K and Sygenus.

Cash position at 30 June 2017 is $4.1 million (30 June 2016 was $0.53 million).

The sources of funding for the company over the next 18 months include: the R&D tax incentive for FY' 17 (forecast >$2.2m) and FY' 18; potential licensing and milestone payments for Progenza; and shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013. These sources of cash should ensure that the company has sufficient funding to support its R&D, clinical trials and operating activities for FY'18 and into FY'19.

Further licensing opportunities will provide additional funding for incremental activities.

To view the Appendix AC - Quarterly Cash Flows Statement, please visit:
http://abnnewswire.net/lnk/0ZB7T344


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

https://plus.google.com/108721050557390681250 https://twitter.com/Regeneus https://www.facebook.com/pages/Regeneus/110433905646491 https://www.youtube.com/user/Regeneus http://www.linkedin.com/company/regeneus-ltd?trk=top_nav_home abnnewswire.com 


Contact

Sandra McIntosh
Investor Relations
T: +61-2-9499-8010
E: investors@regeneus.com.au
W: www.regeneus.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 10) (Last 30 Days: 24) (Since Published: 5107)